- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06850038
Un estudio que observa la efectividad y seguridad a largo plazo de ODVIXIBAT (BYLVAY) en pacientes con síndrome de Alagille (ALG) que reciben tratamiento continuo
Estudio prospectivo basado en el registro que evalúa la efectividad y la seguridad de Odevixibat en participantes con síndrome de Alagille (ALGS)
This study will collect information from patients with Alagille syndrome (ALGS) as they use odevixibat (Bylvay) in their daily lives.
Odevixibat is a medicine that helps patients with ALGS, a rare disease that harms their liver and causes itching.
The main aim of this study is to observe the long-term, everyday effectiveness and safety of the drug odevixibat in patients with ALGS who are receiving ongoing treatment.
Descripción general del estudio
Estado
Condiciones
Tipo de estudio
Inscripción (Estimado)
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Ipsen Recruitment Enquiries
- Número de teléfono: See email
- Correo electrónico: clinical.trials@ipsen.com
Ubicaciones de estudio
-
-
California
-
Los Angeles, California, Estados Unidos, 90027
- Reclutamiento
- Children's Hospital Los Angeles
-
San Francisco, California, Estados Unidos, 94158
- Reclutamiento
- UCSF Benioff Children's Hospital
-
-
Missouri
-
Kansas City, Missouri, Estados Unidos, 64108
- Reclutamiento
- The Children's Mercy Hospital
-
St Louis, Missouri, Estados Unidos, 63104
- Reclutamiento
- SSM Health Cardinal Glennon Children's Hospital
-
-
New York
-
New York, New York, Estados Unidos, 10016
- Reclutamiento
- NYU Langone - NYU Grossman School of Medicine
-
New York, New York, Estados Unidos, 10032
- Reclutamiento
- Columbia University Medical Center - Morgan Stanley Children's Hospital of NewYork - Presbyterian (MS-CHONY)
-
-
Tennessee
-
Memphis, Tennessee, Estados Unidos, 38105
- Reclutamiento
- Le Bonheur Children's Hospital
-
-
Texas
-
Dallas, Texas, Estados Unidos, 75246
- Reclutamiento
- Children's Medical Center Of Dallas
-
El Paso, Texas, Estados Unidos, 79902
- Reclutamiento
- Proactive El Paso,LLC
-
-
Utah
-
Salt Lake City, Utah, Estados Unidos, 84113
- Aún no reclutando
- Primary Children's Hospital (PCH) - Intermountain Healthcare/University of Utah
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
- Niño
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Patients diagnosed with ALGS who start treatment with odevixibat (Bylvay) will be enrolled into the registry. Patients who started odevixibat treatment before the implementation of the registry study may also be enrolled.
Descripción
Inclusion Criteria:
- Diagnosed with ALGS.
- On (or starting) active odevixibat treatment.
- Signed informed consent and assent, as appropriate. Consent/assent from the participant or legal representative should be obtained, as appropriate, before any study data collection is conducted. Participants who turn 18 years of age (or legal age per country) while participating in the study will be required to provide consent for themselves.
Exclusion Criteria:
- Currently participating in a clinical trial with odevixibat.
- Currently participating in any interventional clinical trial for ALGS.
- Have any contraindication to odevixibat as per the locally approved label.
- Had liver transplant before enrolment
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: OTHER
- Perspectivas temporales: PROSPECTIVE
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Porcentaje de participantes con síndrome de Alagille (ALG) que se tratan con ODVIXIBAT y se someten a cirugía de desvío biliar o trasplante de hígado.
Periodo de tiempo: De la primera dosis hasta el final del estudio (aproximadamente 5 años de recopilación de datos)
|
De la primera dosis hasta el final del estudio (aproximadamente 5 años de recopilación de datos)
|
|
|
Surgical biliary diversion-free survival
Periodo de tiempo: From first dose to end of study (approximately 5 years data collection)
|
Defined as time from the start of odevixibat treatment to the first occurrence of surgical biliary diversion or death. |
From first dose to end of study (approximately 5 years data collection)
|
|
Liver transplant-free survival
Periodo de tiempo: From first dose to end of study (approximately 5 years data collection)
|
Defined as time from the start of odevixibat treatment to the first occurrence of liver transplant or death. |
From first dose to end of study (approximately 5 years data collection)
|
|
Overall survival
Periodo de tiempo: From first dose to end of study (approximately 5 years data collection)
|
Defined as time from the start of odevixibat treatment to death. |
From first dose to end of study (approximately 5 years data collection)
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change from Baseline in Weight
Periodo de tiempo: From first dose to end of study (approximately 5 years data collection)
|
This endpoint will measure the change in participants' weight from baseline, reported as standard-deviation scores (z-scores) to account for age and sex-specific growth variations. |
From first dose to end of study (approximately 5 years data collection)
|
|
Change from Baseline in Height
Periodo de tiempo: From first dose to end of study (approximately 5 years data collection)
|
This endpoint will measure the change in participants' height from baseline, reported as standard-deviation scores (z-scores) to account for age and sex-specific growth variations. |
From first dose to end of study (approximately 5 years data collection)
|
|
Percentage of participants with Adverse Events (AEs) associated with fat-soluble vitamin (FSV) deficiencies and their possible sequelae.
Periodo de tiempo: From signing of the Informed Consent Form (ICF) to 180 days after the last dose intake of odevixibat
|
An Adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. |
From signing of the Informed Consent Form (ICF) to 180 days after the last dose intake of odevixibat
|
|
Percentage of participants with suspected hepatotoxic Adverse events (AEs) requiring interruption of odevixibat
Periodo de tiempo: From signing of the ICF to 180 days after the last dose intake of odevixibat
|
An Adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. |
From signing of the ICF to 180 days after the last dose intake of odevixibat
|
|
Percentage of participants with bleeding AEs
Periodo de tiempo: From signing of the ICF to 180 days after the last dose intake of odevixibat
|
An Adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. |
From signing of the ICF to 180 days after the last dose intake of odevixibat
|
|
Percentage of participants with AEs
Periodo de tiempo: From signing of the ICF to 180 days after the last dose intake of odevixibat
|
An Adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. |
From signing of the ICF to 180 days after the last dose intake of odevixibat
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Director de estudio: Ipsen Medical, Director, Ipsen
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Enfermedades cardiovasculares
- Enfermedades Genéticas Congénitas
- Enfermedades del Sistema Digestivo
- Enfermedades del Tracto Biliar
- Enfermedades del HIGADO
- Anomalías congénitas
- Anomalías cardiovasculares
- Defectos Cardíacos Congénitos
- Anomalías Múltiples
- Enfermedades de las vías biliares
- Colestasis Intrahepática
- Colestasis
- Enfermedades y anomalías congénitas, hereditarias y neonatales
- Síndrome de Alagille
Otros números de identificación del estudio
- CLIN-60240-033
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications.
Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants.
Marco de tiempo para compartir IPD
Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the US and/or EU.
Criterios de acceso compartido de IPD
Further details on Ipsen's sharing criteria and process for sharing are available here (https://www.ipsen.com/science/clinical-trials/clinical-data-transparency/).
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .